Halozyme Therapeutics, Inc. (HALO)
Largest Insider Buys in Sector
HALO Stock Price History Chart
HALO Stock Performance
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate …
Insider Activity of Halozyme Therapeutics, Inc.
Over the last 12 months, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $19.59M worth of Halozyme Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Halozyme Therapeutics, Inc. have bought $748,697 and sold $16.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 52,629 shares for transaction amount of $748,697 was made by Kelley Kenneth J (director) on 2020‑03‑19.
List of Insider Buy and Sell Transactions, Halozyme Therapeutics, Inc.
| 2024-10-16 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0074% | $53.26 | $532,590 | -9.07% | ||
| 2024-10-15 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0075% | $53.75 | $537,469 | -9.32% | ||
| 2024-10-09 | Sale | PRESIDENT AND CEO | 10,000 0.0073% | $52.58 | $525,783 | -3.16% | ||
| 2024-10-08 | Sale | PRESIDENT AND CEO | 10,000 0.0075% | $54.00 | $539,961 | -9.37% | ||
| 2024-09-26 | Sale | PRESIDENT AND CEO | 10,000 0.0076% | $56.10 | $560,970 | +1.52% | ||
| 2024-09-25 | Sale | PRESIDENT AND CEO | 10,000 0.0076% | $56.34 | $563,370 | +1.09% | ||
| 2024-09-24 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $58.21 | $582,100 | -2.16% | ||
| 2024-09-18 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0079% | $62.03 | $620,316 | -16.63% | ||
| 2024-09-17 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.008% | $62.88 | $628,780 | -15.82% | ||
| 2024-09-12 | Sale | PRESIDENT AND CEO | 10,000 0.0077% | $59.20 | $592,030 | -13.37% | ||
| 2024-09-11 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $59.09 | $590,870 | +2.46% | ||
| 2024-09-10 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $59.09 | $590,890 | -11.22% | ||
| 2024-08-21 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0078% | $61.75 | $617,470 | -10.91% | ||
| 2024-08-20 | Sale | SVP, CHIEF TECHNICAL OFFICER | 10,000 0.0079% | $61.05 | $610,550 | -7.04% | ||
| 2024-08-15 | Sale | PRESIDENT AND CEO | 10,000 0.0082% | $57.95 | $579,490 | 0.00% | ||
| 2024-08-14 | Sale | PRESIDENT AND CEO | 10,000 0.0081% | $57.25 | $572,471 | 0.00% | ||
| 2024-08-14 | Sale | director | 9,881 0.0081% | $57.70 | $570,134 | 0.00% | ||
| 2024-08-13 | Sale | PRESIDENT AND CEO | 10,000 0.0079% | $56.25 | $562,490 | 0.00% | ||
| 2024-08-13 | Sale | director | 10,000 0.0079% | $56.19 | $561,930 | 0.00% | ||
| 2024-08-12 | Sale | director | 10,000 0.0079% | $55.72 | $557,230 | +1.61% |
Insider Historical Profitability
| Torley Helen | PRESIDENT AND CEO | 676744 0.5319% | $47.17 | 1 | 44 | +68.25% |
| Frost Gregory Ian | CEO, President | 3555331 2.7945% | $47.17 | 4 | 16 | +20.07% |
| KIRK RANDAL J | 10 percent owner | 1897610 1.4915% | $47.17 | 56 | 18 | +103.31% |
| Lim Jonathan E | President, CEO | 680000 0.5345% | $47.17 | 1 | 8 | +18.01% |
| RAMSAY DAVID A | VP and Chief Financial Officer | 323492 0.2543% | $47.17 | 7 | 3 | +24.44% |
Institutional Investor Ownership
| BlackRock | $742.07M | 14.33 | 18.24M | -2.09% | -$15.84M | 0.02 | |
| The Vanguard Group | $530.84M | 10.25 | 13.05M | -1.59% | -$8.55M | 0.01 | |
| State Street | $263.9M | 5.1 | 6.49M | +0.18% | +$478,152.72 | 0.01 | |
| Right Side Capital Management | $167.49M | 3.24 | 4.12M | +10.99% | +$16.58M | 3.59 | |
| Artisan Partners | $154.23M | 2.98 | 3.79M | -43.32% | -$117.88M | 0.23 |